Trial progresses towards topline data expected later in the year

FDA recognises KER-0193 as a potential therapy for rare paediatric disease

Screening begins for study evaluating LTI-03 in idiopathic pulmonary fibrosi

Private equity firm Apiary Capital backs rapid growth of performance-i

Teprotumumab approved as first targeted treatment for thyroid eye disease

Study explores whether PI3Kδ targeting could combat resistance

UCB’s developmental treatment may be eligible for patient access

New initiative aims to accelerate diagnosis and ease NHS pressures

Company seeks approval for new schedules to improve patient convenience